Precision BioSciences (NASDAQ:DTIL) shares are trading higher on Wednesday after the company announced it received fast track designation from the FDA for its PBCAR269A investigational allogeneic CAR T therapy for relapsed and refractory Multiple Myeloma.
Precision BioSciences is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.
Precision BioSciences shares were trading up 2.63% at $5.47 at the time of publication Wednesday. The stock has a 52-week high of $23.67 and a 52-week low of $4.46.